Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.
Authors
Dean, Emma JMiddleton, M R
Pwint, T
Swaisland, H
Carmichael, J
Goodege-Kunwar, P
Ranson, Malcolm R
Affiliation
Clinical Trials Unit, Department of Medical Oncology, The Christie NHS Foundation Trust, The University of Manchester, Wilmslow Road, Manchester M20 4, BX, UK. emma.dean@christie.nhs.ukIssue Date
2012-01-31
Metadata
Show full item recordAbstract
Olaparib (AZD2281) is a potent oral poly(ADP-ribose) polymerase inhibitor with anti-tumour activity and acceptable toxicity as monotherapy in patients with BRCA-deficient cancers. The vascular endothelial growth factor receptor inhibitor bevacizumab has been incorporated into standard of care with chemotherapy in various tumours. This phase I study established the safety, tolerability and clinical pharmacokinetics of olaparib alone and in combination with bevacizumab.Citation
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. 2012, 106 (3):468-74 Br J CancerJournal
British Journal of CancerDOI
10.1038/bjc.2011.555PubMed ID
22223088Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2011.555